
Nebraska Medicine
4350 Dewey Ave., Omaha, NE, 68105, United States
Overview
Nebraska Medicine is the most esteemed academic health system in the region, consisting of 809 licensed beds at its two hospitals, more than 1,000 physicians and 40 specialty and primary care clinics in Omaha and surrounding areas. Nebraska Medicine and its research and education partner, the University of Nebraska Medical Center (UNMC), share the same mission: to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care. Nebraska Medicine traces its roots back to 1869 with the founding of Omaha’s first hospital. In the decades since, it has built an international reputation for breakthroughs in cancer care, organ transplantation and treatment of infectious diseases. In 2016, Nebraska Medicine earned the Bernard A. Birnbaum, MD Quality Leadership Award from Vizient, Inc. which recognizes it in the top ten quality academic health systems in the United States. For three straight years, Nebraska Medicine has also been named to Becker’s Hospital Review’s list of 100 Great Hospitals in America.
- Total investments
- 4
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 4
Sector focus
- Education
- Health Care
Investment portfolio
- Judy Rx
Participated · Equity · Oct 2023
Capital Rx operates a cloud-native pharmacy benefit management (PBM) platform that adjudicates prescription drug claims and provides price transparency to employers, insurers, and other payers. The company is now broadening its technology to handle medical claims as well, positioning itself as an end-to-end claims processor across both pharmacy and medical benefits. By unifying these workflows, Capital Rx aims to give payers better visibility into total healthcare spending and negotiate more favorable rates. Management says the fresh capital will accelerate product expansion and support additional hiring to meet customer demand. The firm reports an oversubscribed funding round and cites strong interest from new and existing investors. A spokesperson disclosed that Capital Rx now carries a $3.25 billion valuation, underscoring investor confidence in its growth trajectory. Although detailed revenue or user metrics were not provided, the company emphasized that the additional funds will enable it to scale its platform nationwide.
- Nudj Health
Led · Series A · Apr 2022
Nudj Health provides virtual care infrastructure that integrates behavioral health treatments into primary and specialty care using the collaborative care model and evidence-based, Medicare-approved clinical pathways. Its approach centers on six lifestyle areas: stress management, physical activity, sleep quality, social support, behavioral risks and nutrition. The company reports clinical effectiveness—moderate to severe depression, anxiety, and insomnia scores decreased 42–52% within 12 weeks—and patients experienced blood pressure and weight reduction or maintenance, improved mobility, and better medication adherence. Nudj has already integrated its service with several cardiology and oncology providers across the U.S. The company announced a $10 million Series A and plans to use the capital to grow clinical, technology, and commercial teams. Its stated goal is to rapidly scale turnkey, evidence-based behavioral health services in cardiology, oncology and primary care settings nationwide.
- Xealth
Participated · Series B · Sep 2021
Xealth is a Seattle-based company that develops digital health enablement solutions for health systems. Its platform allows providers to prescribe and monitor digital health content, apps, and services as easily as medications. The platform incorporates custom data and analytics so health systems can track, analyze, and evaluate digital health use through its integration platform. Led by CEO Mike McSherry, Xealth reports 12 million orders sent, 100,000 providers engaged, and three million patients reached to date. The company received an investment from Morningside Ventures and intends to use the funds to expand operations and its development efforts. The amount and instrument of the investment were not disclosed in the announcement. Xealth provides a platform that centralizes integration, prescribing, monitoring and governance for digital health tools within clinician workflows. The platform is tightly integrated with EHRs and has full integrations with the largest EHR vendors. It is available to more than 100,000 physicians and its deployments demonstrate a 50–80% reduction in integration and deployment costs while driving substantial patient engagement. Xealth is backed by health systems and strategic investors, including Cerner, Novartis, Philips, ResMed, McKesson Ventures, Threshold Ventures and LRV Health. The company plans to use the new funding to roughly double its team and to fund product innovation, including enhancements to its intelligence engine to better match tools to patients and scale deployments across the U.S. Spun out of Providence St. Joseph Health in 2017 and based in Seattle, Xealth has raised $52.6 million to date. Xealth provides a platform that enables health systems to organize, integrate, deploy and activate digital health tools and programs. Through the platform, clinicians can find and order digital health tools directly from the EHR workflow, send those digital orders to patients' smartphones or desktops, monitor patient engagement and analyze the effects of more engaged patients. The company raised an additional $3M in its Series A, bringing the round to $14M total, and intends to use the funds to advance development and deployment of its platform for digital health programs. Xealth spun out of Providence St. Joseph Health in 2017 and is led by CEO Mike McSherry; it is based in Seattle, Washington. It works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Duke Health and other leading health systems. Xealth is a digital prescribing platform that enables clinicians to integrate, prescribe and monitor digital health tools for patients from their EHR workflows. Its platform supports patient education, online third-party apps and programs, device monitoring, and non-clinical services such as ride shares, food delivery and e-commerce recommendations. Care teams and physicians can monitor patient engagement and analyze the effects of more engaged patients. Originally incubated and spun out of Providence St. Joseph Health in 2017 and led by CEO Mike McSherry, the company is based in Seattle, WA. Xealth works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Baylor Scott and White, and Duke. The company raised $11m in a Series A to accelerate expansion of its platform. Xealth is launching a digital prescribing and analytics platform that lets physicians and clinicians prescribe and track educational health content, disease-management apps, and monitoring devices directly from their EMR charting interface. The platform aggregates and filters a variety of content sources into a care provider’s existing EMR workflow, simplifying creation of a customized patient experience. Clinicians can discuss digital tools during appointments, track patient usage afterward, and schedule reminders to encourage engagement. Patients access prescribed digital health tools through their health system’s secure patient portal. Xealth was founded in 2016 by Mike McSherry and was incubated within Providence’s Digital Innovation Group. The company has raised $8.5M to support launch and expansion with participating health systems planning broader integration and use of third-party digital solutions.
- Geneva Health Solutions
Led · Series A · Feb 2017
Geneva Health Solutions (formerly Geneva Healthcare) offers a cloud-based API framework and telehealth monitoring service that aggregates remote transmissions from implanted cardiac devices. The platform pulls cardiac device data from the four major device manufacturers’ remote monitoring portals and is designed to integrate with clinic workflow and EMRs. GHS combines technology, telehealth and consulting to help cardiology practices manage the increasing volume of remote-monitoring data and improve clinic workflow. The company announced a $1.9 million Series A to fund expansion of its cardiac remote monitoring solutions to cardiology providers. Management says the funding will speed onboarding of cardiology practices across the country to its platform. CEO Yuri Sudhakar framed the product as enabling data-driven patient care as more medical devices push data remotely.